Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PER2 | O15055 | 7/20 | 0.37 |
| ▸ | CRY2 | Q49AN0 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24256488 | 0.82 | PIK3CD (0.67) | PIK3CDPOLBPER2CRY2HDAC1 | |
| SCHEMBL19701910 | 0.78 | PIK3CD (1.00) | PIK3CDPOLBPER2CRY2 | |
| SCHEMBL23469785 | 0.78 | PIK3CD (0.61) | PIK3CDPOLBPER2CRY2HDAC1 | |
| SCHEMBL27151784 | 0.78 | PIK3CD (0.61) | PIK3CDPOLBPER2CRY2HDAC1 | |
| SCHEMBL16190280 | 0.78 | — | — | |
| SCHEMBL1524638 | 0.78 | — | — | |
| SCHEMBL7506934 | 0.77 | PIK3CD (0.65) | PIK3CDPOLBPER2CRY2HDAC1 | |
| SCHEMBL18664136 | 0.77 | PIK3CD (0.65) | PIK3CDPOLBPER2CRY2 | |
| SCHEMBL18664138 | 0.77 | PIK3CD (0.65) | PIK3CDPOLBPER2CRY2 | |
| SCHEMBL18664137 | 0.77 | PIK3CD (0.65) | PIK3CDPOLBPER2CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044731-A1 | DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY | MATCHPOINT THERAPEUTICS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | BROADENBIO CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| WO-2021083011-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF | 北京伯汇生物技术有限公司 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | FGFR4, FGFR1, FGFR3 | PIK3CD 815/4885POLB 1151/4885PER2 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.